Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
17,543,860
-
Total 13F shares
-
6,285,927
-
Share change
-
+1,141,789
-
Total reported value
-
$27,416,349
-
Price per share
-
$4.36
-
Number of holders
-
30
-
Value change
-
+$4,969,639
-
Number of buys
-
22
-
Number of sells
-
4
Institutional Holders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value (UNCY) as of Q3 2025
As of 30 Sep 2025,
Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value (UNCY) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,285,927 shares.
The largest 10 holders included
Vivo Capital, LLC, Octagon Capital Advisors LP, Nantahala Capital Management, LLC, GREAT POINT PARTNERS LLC, VANGUARD GROUP INC, Logos Global Management LP, GEODE CAPITAL MANAGEMENT, LLC, Squarepoint Ops LLC, ACUTA CAPITAL PARTNERS, LLC, and STATE STREET CORP.
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.